This event marks the beginning of a key project, opening a significant step in the long-term partnership to enhance treatment quality for patients and contribute to improving Vietnam’s healthcare system.
At the event, representatives from FPT Long Châu and AstraZeneca Vietnam updated in-depth medical knowledge, consultation skills for pharmacists across the entire system, and raised awareness of patient health care, thus driving adherence to treatment protocols and contributing practical value to the community.
The year 2025 is a special milestone in the 10-year journey of using active substances for cardiovascular, renal, and metabolic diseases, researched and manufactured by AstraZeneca, in the Vietnamese market. This therapy has been further approved by the FDA (US Food and Drug Administration) for a new indication in the treatment of chronic kidney disease, alongside type 2 diabetes and heart failure.
This advancement in medicine further affirms the superior value of a solution capable of impacting three major chronic diseases affecting public health, including diabetes, heart failure, and chronic kidney disease.
According to medical experts, cardiovascular, renal, and metabolic diseases are closely related, often coexist, and can exacerbate each other’s conditions.
Therefore, treating chronic kidney disease isn’t about treating a single condition; it requires simultaneous treatment and protection for all three diseases. This approach also opens up opportunities to comprehensively improve the health of millions of patients, helping to alleviate the burden on the national healthcare system.
At the seminar, Mr. Atul Tandon, Managing Director of AstraZeneca Vietnam, shared: “AstraZeneca’s mission in the biological pharmaceutical sector is driven by a passion to understand and address patients’ needs, discover and develop advanced treatments, and strengthen close collaboration with local partners to improve patients’ quality of life.
The partnership between AstraZeneca Vietnam and FPT Long Châu exemplifies this mission, as we collaborate to introduce advanced treatments and bring hope to the community we serve.”
Ms. Nguyễn Đỗ Quyên, Deputy General Director of FPT Retail and CEO of FPT Long Châu’s Pharmacy and Vaccination System, stated: “Over the past four years of strategic cooperation, we are proud to have implemented numerous community activities with AstraZeneca Vietnam, trained thousands of pharmacists, and connected with leading medical experts.
With over 16,000 pharmacists serving 26 million customers, FPT Long Châu is committed to continuing as an extension of the healthcare industry, partnering closely with AstraZeneca for a healthy Vietnam.”
Long Châu, committed to building a comprehensive healthcare ecosystem, affirms the crucial role of medical and pharmacy staff, ensuring adherence to the criteria of providing the correct medication, diagnosis, and dosage, contributing to improved treatment adherence and comprehensive health care, Ms. Nguyễn Đỗ Quyên emphasized.
